Cultures were maintained in a humidified atmosphere of 5% CO 2 at 37C for 24 h and then incubated for the next 24-h period in DMEM-10% HS additionally containing recombinant HGF that was treated with peroxynitrite with or without trisulfide pre-treatment (see Figure 1d,f)
Why GLP-1 medications cause constipation in the first place Understanding the mechanism matters
The ongoing Phase II petrelintide monotherapy trial, ZUPREME-2 is evaluating petrelintide versus placebo in people living with obesity or overweight and T2D
Body Composition Preservation: While older weight-loss methods stripped both fat and muscle, GLP-1 therapycombined with adequate protein and resistance exercise, preferentially preserves lean muscle mass, protecting your metabolic rate and functional capacity
How The Doctor Chooses: A Practical Approach The decision to choose these medications follow a simple path: Clarify goals: Is the priority blood-sugar control, weight loss, or both